OverviewSuggest Edit

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. The Company has a platform for discovering proprietary compounds that work through a modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.

TypePublic
Founded2015
HQEvanston, IL, US
Websiteaptinyx.com

Latest Updates

Employees (est.) (Mar 2019)63(+5%)
Job Openings1
Revenue (FY, 2020)$1.6 M(-57%)
Share Price (May 2021)$2.7
Cybersecurity ratingBMore

Key People/Management at Aptinyx

Patrick Enright

Patrick Enright

Chairman
Juan Estupinan

Juan Estupinan

Vice President, Finance & Accounting and Controller
Henry O. Gosebruch

Henry O. Gosebruch

Director
Betty Jang

Betty Jang

Vice President, Head of Legal and Corporate Secretary
Ashish Khanna

Ashish Khanna

Chief Financial Officer & Chief Business Officer
Rachel Sherman

Rachel Sherman

Director
Show more

Aptinyx Office Locations

Aptinyx has an office in Evanston
Evanston, IL, US (HQ)
909 Davis St #600
Evanston, IL, US
1801 Maple Ave #4300
Show all (2)

Aptinyx Financials and Metrics

Aptinyx Revenue

Aptinyx's revenue was reported to be $1.56 m in FY, 2020
USD

Revenue (FY, 2020)

1.6m

Net income (FY, 2020)

(50.1m)

EBIT (FY, 2020)

(50.8m)

Market capitalization (3-May-2021)

179.5m

Closing stock price (3-May-2021)

2.7

Cash (31-Dec-2020)

141.0m
Aptinyx's current market capitalization is $179.5 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

6.6m3.7m1.6m

General and administrative expense

12.7m19.0m19.5m

R&D expense

48.8m44.3m32.8m

Operating expense total

61.5m63.3m52.3m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.1m943.0k890.0k925.0k936.0k818.0k490.0k

General and administrative expense

2.0m3.8m5.7m4.2m4.5m4.9m4.8m

R&D expense

13.7m12.0m12.5m9.5m11.8m11.1m8.4m

Operating expense total

15.7m15.7m18.2m13.7m16.3m16.0m13.1m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

150.6m98.8m141.0m

Accounts Receivable

578.0k444.0k257.0k

Prepaid Expenses

1.8m5.6m8.1m

Current Assets

153.3m105.1m149.6m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

179.1m165.6m136.6m124.9m114.2m121.0m115.9m

Accounts Receivable

1.0m593.0k415.0k450.0k461.0k818.0k490.0k

Prepaid Expenses

371.0k1.2m1.5m2.9m4.0m4.1m3.7m

Current Assets

180.5m167.6m138.8m128.5m118.8m126.1m120.2m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(53.3m)(57.4m)(50.1m)

Depreciation and Amortization

457.0k421.0k

Accounts Payable

418.0k(361.0k)(340.0k)

Cash From Operating Activities

(47.4m)(52.1m)(42.4m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(25.0m)(39.2m)(16.7m)(28.8m)(43.6m)(14.7m)(27.2m)

Depreciation and Amortization

216.0k336.0k117.0k233.0k345.0k211.0k

Accounts Payable

109.0k(263.0k)(553.0k)(1.1m)(139.0k)134.0k(60.0k)

Cash From Operating Activities

(20.2m)(32.5m)(14.1m)(25.9m)(36.6m)(11.6m)(21.3m)
USDQ2, 2018

Revenue/Employee

44.8k

Financial Leverage

1 x
Show all financial metrics

Aptinyx Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Aptinyx Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Aptinyx Online and Social Media Presence

Embed Graph

Aptinyx News and Updates

Thinking about buying stock in Aptinyx, Acorda Therapeutics, T-Mobile, Best Buy, or Advanced Micro Devices?

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APTX, ACOR, TMUS, BBY, and AMD. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Aptinyx stock soars on premarket leading volume after positive trial results of PTSD treatment

Shares of Aptinyx Inc. shot up 61% on heavy volume in premarket trading Tuesday, putting them on track to open at a 20-month high, after the biopharmaceutical company reported positive results from a Phase 2 trial of its treatment for post-traumatic stress disorder (PTSD). Trading volume was 14.6 m…

Aptinyx Completes Enrollment in Phase 2 Exploratory Study of NYX-783 in Post-Traumatic Stress Disorder

Data readout expected by late 2020 Data readout expected by late 2020

Aptinyx to Present at Upcoming Virtual Investor Conferences

EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the following upcomin…

Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference

EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the …

Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease

Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease
Show more

Aptinyx Blogs

Aptinyx Reports First Quarter 2020 Financial Results and Highlights

Aptinyx Reports First Quarter 2020 Financial Results and Highlights Content Import Thu, 05/14/2020 - 16:03 Aptinyx Reports First Quarter 2020 Financial Results and Highlights May 14, 2020 This release is a backfill from a News Wire Earnings Over 90…

Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020

Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020 Content Import Thu, 04/30/2020 - 08:47 Aptinyx to Report First Quarter Financial Results on Thursday, May 14, 2020 April 30, 2020 This release is a backfill from a News Wire General …

Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common stock offering provides runway into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill.

Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease

Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease Content Import Thu, 01/30/2020 - 07:07 Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cogniti…

Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option

EVANSTON, Ill. , Jan. 14, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the closing of its public offering of 11,691,666 shares of its

Aptinyx Announces Pricing of Public Offering of Common Stock

Aptinyx Announces Pricing of Public Offering of Common Stock Content Import Fri, 01/10/2020 - 09:00 Aptinyx Announces Pricing of Public Offering of Common Stock January 10, 2020 This release is a backfill from a News Wire General EVANSTON, Ill., Ja…
Show more

Aptinyx Frequently Asked Questions

  • When was Aptinyx founded?

    Aptinyx was founded in 2015.

  • Who are Aptinyx key executives?

    Aptinyx's key executives are Patrick Enright, Juan Estupinan and Henry O. Gosebruch.

  • How many employees does Aptinyx have?

    Aptinyx has 63 employees.

  • What is Aptinyx revenue?

    Latest Aptinyx annual revenue is $1.6 m.

  • What is Aptinyx revenue per employee?

    Latest Aptinyx revenue per employee is $24.8 k.

  • Who are Aptinyx competitors?

    Competitors of Aptinyx include XBiotech, Rubius Therapeutics and Atara Biotherapeutics.

  • Where is Aptinyx headquarters?

    Aptinyx headquarters is located at 909 Davis St #600, Evanston.

  • Where are Aptinyx offices?

    Aptinyx has an office in Evanston.

  • How many offices does Aptinyx have?

    Aptinyx has 2 offices.